High Serum Cyclophilin C levels as a risk factor marker for Coronary Artery Disease.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 07 2019
Historique:
received: 22 11 2018
accepted: 09 07 2019
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 27 10 2020
Statut: epublish

Résumé

Cyclophilins (Cyps) are ubiquitous proteins that belong to the immunophilins family consistently associated with inflammatory and cardiovascular diseases. While levels of CypA have been extensively studied, less data are available for other Cyps. The purpose of this case-control study was to determine the relationship of Cyps (A, B, C and D) with coronary artery disease (CAD) and eight inflammation markers. Serum levels of Cyps, interleukins and metalloproteinases were measured in serum collected from 84 subjects. Participants were divided into two sub-groups based on CAD diagnosis: 40 CAD patients and 44 control volunteers. Serum levels of CypA, CypB and CypC, IL-1β and IL-6 were significantly higher in CAD patients. Bivariate correlation analysis revealed a significant positive correlation between Cyps and several blood and biochemical parameters. When the ability of Cyps levels for CAD diagnosis was evaluated, higher sensitivity and selectivity values were obtained with CypC (c-statistic 0.891, p < 0.001) indicating that it is a good marker of CAD disease, while less conclusive results were obtained with CypA (c-statistic 0.748, p < 0.001) and CypB (c-statistic 0.655, p < 0.014). In addition, significant correlations of traditional CAD risk factors and CypC were observed. In summary, high levels of CypC are a risk factor for CAD and therefore it can be proposed as a new biomarker for this disease.

Identifiants

pubmed: 31332225
doi: 10.1038/s41598-019-46988-x
pii: 10.1038/s41598-019-46988-x
pmc: PMC6646393
doi:

Substances chimiques

Biomarkers 0
Peptidyl-Prolyl Isomerase F 0
cyclophilin B 137497-17-7
Cyclophilin A EC 5.2.1.-
Cyclophilins EC 5.2.1.-
Cyclophilin C EC 5.2.1.8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10576

Références

Arthritis Res Ther. 2012 Jul 19;14(4):122
pubmed: 22808986
Int J Mol Sci. 2018 Feb 08;19(2):
pubmed: 29419744
Sci Rep. 2015 Apr 24;5:9937
pubmed: 25909510
J Cereb Blood Flow Metab. 2005 Mar;25(3):325-37
pubmed: 15647740
Stat Med. 2011 May 10;30(10):1105-17
pubmed: 21484848
Curr Mol Pharmacol. 2015;9(1):37-47
pubmed: 25986569
Front Endocrinol (Lausanne). 2017 Dec 22;8:360
pubmed: 29312150
Cardiovasc Res. 2009 Jul 15;83(2):335-44
pubmed: 19299432
J Biol Chem. 2000 Jan 7;275(1):189-96
pubmed: 10617604
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10214-9
pubmed: 20479245
Cardiovasc Res. 2015 Jun 1;106(3):353-64
pubmed: 25750190
Brain Res. 2011 Jun 23;1397:55-65
pubmed: 21435337
J Am Heart Assoc. 2017 Oct 24;6(10):
pubmed: 29066452
Plant Signal Behav. 2013 Jan;8(1):e22734
pubmed: 23123451
J Mol Cell Cardiol. 2015 Jan;78:80-9
pubmed: 25281838
Indian Pediatr. 2011 Apr;48(4):277-87
pubmed: 21532099
Cytokine Growth Factor Rev. 2018 Feb;39:62-70
pubmed: 29396056
Circ J. 2013;77(2):447-55
pubmed: 23138189
Tohoku J Exp Med. 2015;235(1):1-15
pubmed: 25743766
Redox Biol. 2018 May;15:418-434
pubmed: 29353219
Atherosclerosis. 2010 Dec;213(2):415-21
pubmed: 21035802
Circ Res. 2016 Feb 19;118(4):535-46
pubmed: 26892956
J Biol Chem. 2014 Aug 15;289(33):23086-96
pubmed: 24990953
World J Diabetes. 2015 Oct 10;6(13):1246-58
pubmed: 26468341
Nat Rev Cardiol. 2017 Feb;14(2):69-70
pubmed: 28054573
Cardiovasc Diabetol. 2014 Feb 07;13:38
pubmed: 24502618
Clin Immunol. 2005 Sep;116(3):217-24
pubmed: 15993649
Biochim Biophys Acta. 2015 Oct;1850(10):2087-95
pubmed: 25445705
Ann Rheum Dis. 2005 Nov;64(11):1595-601
pubmed: 15843450
Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):685-693
pubmed: 28153875
Biol Chem. 2014 Jul;395(7-8):721-35
pubmed: 24713575
Heart. 2016 Dec 15;102(24):1937-1939
pubmed: 27540179
World J Diabetes. 2014 Aug 15;5(4):444-70
pubmed: 25126392
Curr Mol Pharmacol. 2015;9(2):165-79
pubmed: 25986561

Auteurs

Amparo Alfonso (A)

Pharmacology Department, Facultad de Veterinaria, Universidad de Santiago de Compostela, 27002, Lugo, Spain. amparo.alfonso@usc.es.

Jeremías Bayón (J)

Cardiology Department, Hospital Universitario Lucus Augusti, 27003, Lugo, Spain.

Sandra Gegunde (S)

Pharmacology Department, Facultad de Veterinaria, Universidad de Santiago de Compostela, 27002, Lugo, Spain.

Eva Alonso (E)

Pharmacology Department, Facultad de Veterinaria, Universidad de Santiago de Compostela, 27002, Lugo, Spain.

Rebeca Alvariño (R)

Pharmacology Department, Facultad de Veterinaria, Universidad de Santiago de Compostela, 27002, Lugo, Spain.

Melisa Santás-Álvarez (M)

Cardiology Department, Hospital Universitario Lucus Augusti, 27003, Lugo, Spain.

Ana Testa-Fernández (A)

Cardiology Department, Hospital Universitario Lucus Augusti, 27003, Lugo, Spain.

Ramón Rios-Vázquez (R)

Cardiology Department, Hospital Universitario Lucus Augusti, 27003, Lugo, Spain.

Carlos González-Juanatey (C)

Cardiology Department, Hospital Universitario Lucus Augusti, 27003, Lugo, Spain.

Luis M Botana (LM)

Pharmacology Department, Facultad de Veterinaria, Universidad de Santiago de Compostela, 27002, Lugo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH